These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35235002)

  • 1. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
    J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
    Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
    Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    Capuano R; Altieri M; Conte M; Bisecco A; d'Ambrosio A; Donnarumma G; Grimaldi E; Coppola N; Medici N; Galdiero M; Tedeschi G; Gallo A
    J Neurol; 2022 Dec; 269(12):6185-6192. PubMed ID: 35879563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.
    Barone S; Palmieri C; Gallelli L; Rania V; Pascarella A; Abatino A; Bruno PA; Casarella A; Pasquale M; Manzo L; De Sarro G; Gambardella A; Valentino P
    Neurotherapeutics; 2024 Mar; 21(2):e00307. PubMed ID: 38237381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
    Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
    Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
    JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
    Idda ML; Pitzalis M; Lodde V; Loizedda A; Frau J; Lobina M; Zoledziewska M; Virdis F; Delogu G; Marini MG; Mingoia M; Masala M; Lorefice L; Fronza M; Carmagnini D; Carta E; Pilotto S; Castiglia P; Chessa P; Uzzau S; Farina G; Solla P; Steri M; Devoto M; Fiorillo E; Floris M; Zarbo RI; Cocco E; Cucca F
    Front Immunol; 2022; 13():946356. PubMed ID: 36059537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
    Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
    Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
    Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
    Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
    Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
    Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.